APA (7th ed.) Citation

D, K., C, K., CD, H., Y, S., TT, T., K, K., . . . SM, T. (2015). Mitigation of Tumor-Associated Fibroblast-Facilitated Head and Neck Cancer Progression With Anti-Hepatocyte Growth Factor Antibody Ficlatuzumab. JAMA otolaryngology-- head & neck surgery, 141(12), 1133. https://doi.org/10.1001/jamaoto.2015.2381

Chicago Style (17th ed.) Citation

D, Kumar, et al. "Mitigation of Tumor-Associated Fibroblast-Facilitated Head and Neck Cancer Progression With Anti-Hepatocyte Growth Factor Antibody Ficlatuzumab." JAMA Otolaryngology-- Head & Neck Surgery 141, no. 12 (2015): 1133. https://doi.org/10.1001/jamaoto.2015.2381.

MLA (9th ed.) Citation

D, Kumar, et al. "Mitigation of Tumor-Associated Fibroblast-Facilitated Head and Neck Cancer Progression With Anti-Hepatocyte Growth Factor Antibody Ficlatuzumab." JAMA Otolaryngology-- Head & Neck Surgery, vol. 141, no. 12, 2015, p. 1133, https://doi.org/10.1001/jamaoto.2015.2381.